• Home
  • » 
  • Reports
  • » 
  • BBB Technologies: Novel CNS Drug Deliver...

Blood-Brain Barrier

BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030

  • Lowest Price Guaranteed From USD 2,199

  • Published
    May 2015

  • Pages
    219

  • View Count
    6372

  • Buy Now

Example Insights

An updated edition is available at the following link 

View 2nd edition

  1. More than 25 companies have developed proprietary non-invasive BBB technologies. Majority of these companies are either university spin-offs or start-up firms. Some pharma giants, such as Roche, AbbVie and Genzyme, have also deployed their expertise to develop novel technology platforms.
  2. Majority of BBB technologies (53%) are based on the process of receptor mediated transcytosis (RMT). Within RMT, Trojan horse is the most common strategy. Several companies, such as Armagen, Vect-Horus, and Angiochem, have utilized this approach to transport therapeutics into the brain.
  3. These technology developers are evaluating their technologies on over 50 drug candidates spread across different development stages. 80% of these drugs are undergoing either preclinical or proof of concept and efficacy studies.
  4. Based on several parameters, such as target patient population, and competition (both in terms of number of pipeline and marketed drugs), we believe that indications such as Alzheimer’s disease, epilepsy, and Parkinson’s disease offer a very lucrative future for this market.
  5. Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of BBB technologies market. In fact, during our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts.
  6. The first batch of BBB permeable drugs,based on these technologies, is anticipated to be launched in 2019/2020; post this, we expect the momentum to rise steadily trending towards a multi-billion dollar market by 2030.

Report Description

View Latest Edition

Several people across the globe suffer from different neurological disorders. However, the drugs currently available in the market provide only symptomatic relief and do not treat the root cause. This is because of their inability to penetrate across the blood brain barrier (BBB). BBB is a highly selective permeable membrane which allows the entry of only specific molecules, across it, into the brain. The widening gap between the demand of effective treatments and supply of BBB permeable drugs is going to provide a major impetus to the BBB market in the coming decade. Several pharma companies have identified the unmet need and have developed proprietary technologies. These technologies cater to the aforementioned concerns and are being deployed to develop drugs and APIs that penetrate across the barrier and reach the brain at therapeutically active amounts. Once approved, these drugs are likely to park a major share of the total market.

With growing advances in R&D, and the increasing demands for specific drugs, BBB technologies have become one of the key focus areas of researchers and companies across the world. Several venture capital firms have backed the start-ups working in this field. In addition, partnerships and collaborations have played a pivotal role in the advancement of this market. Many smaller companies, as a part of their business model, are looking to out-license their technologies to the established players in this industry.

 

Scope of the Report

The ‘BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030’ report provides an extensive study of the emerging market of BBB technologies and associated drugs for neurologic diseases. The focus of this study is primarily on the technologies that are non-invasive in nature. There are other technologies which either disrupt the barrier or use an alternate route to bypass it. These technologies are, for the purpose of this report, considered competing in nature. The report covers various aspects such as research pipeline, technological profiles, recent developments and sales forecast to assess new evolving opportunities. We have also provided a competitive market analysis to compare the potential that resides in the leading neurological indications, such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis and brain cancer, for which BBB permeable drugs are being developed.

In addition to the well-known technologies, we have also provided case studies on four other technologies; these are either in direct competition or have been previously worked upon. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different technology providers in this industry.

One of the key objectives of this report is to understand the future state of the BBB technologies market. This is done by analyzing the following:

  • Pipeline candidates based on these technologies
  • Size of target consumer segments
  • Expected launch year and countries where these clinical stage candidates are likely to receive commercialization rights
  • Likely price points

The base year for the report is 2014. The report provides market forecasts for the period 2019 - 2030. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2   provides an executive summary of the insights captured in our research. It offers a high level view on the current scenario of the market of BBB technologies and the likely mid-long term evolution.

Chapter 3   provides a general overview of the central nervous system. It talks about the structure of blood brain barrier, its functions, historical evolution and recent milestones. We have covered, in detail, different methods of CNS drug delivery. The chapter also outlines several strategies that have been worked upon to transport the drugs and therapeutics across the barrier. In addition, the limitations of CNS drug delivery are also highlighted in this chapter.

Chapter 4   provides the list of technology developers who have developed proprietary BBB technologies. Itoffers an extensive pipeline of all the drugs that are being developed by deploying these technologies.The pipeline analysis includes information on the phase of development, nature of drugs, targeted indications etc. We have also covered details of additional drugs which are able to penetrate the BBB but are not based on any underlying technology.

Chapter 5   offers an insightful discussion onsix most popular indications targeted by the BBB permeable drugs under development. This analysis revolves around current landscape, prevailing competition, anticipated shift in the market trend and the key focus for the future.

Chapter 6   covers, in detail, the underlying strategies based on which BBB technologies have been devised. These include receptor mediated transcytosis (RMT), increasing permeability and passive diffusion approach. Within RMT, we have provided the details of bispecific antibodies approach and trojan horse mediated delivery either by direct coupling or by using nano-carriers. 

Chapter 7   provides detailed profiles of all the BBB proprietary platforms, based on aforementioned strategies, under development by different technology developers. These profiles include details of the technology, a brief company overview,relevant partnerships and fundings received by the company, related recent developments and milestones, history of development and associated patents (wherever details were available). 

Chapter 8   provides case studies on four technologies (Intrathecal drug delivery platform, TTP technology, BioMarin technology platform and NeuroTrans technology) outlining their unique technology / platform features.

Chapter 9   presents a scenario based approach to identify the future evolution of the industry. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry’s evolution.

Chapter 10   is a collection of transcripts based on our discussion with some of the upcoming players in the industry such as Ossianix, biOasis, and Sagetis Biotech.

Chapter 11   summarizes the overall report. In this chapter, we provide a recap of the key takeaways and a brief description of some of the emerging technologies that are expected to invade the market in future.

Chapters 12 and 13   are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. BLOOD BRAIN BARRIER: AN INTRODUCTION
3.1. Overview
3.2. Structure of Human Brain
3.3. Strategies for Drug Delivery to the CNS
3.3.1. Systemic Administration of Therapeutics
3.3.2. Direct Administration of Therapeutics
3.3.3. Drug Delivery by Manipulation of the Drug
3.3.4. Chemical Delivery Systems
3.3.5. Drug Delivery Using Devices
3.4. Blood Brain Barrier
3.4.1. Historical Evolution
3.4.2. Structure
3.4.3. Associated Functions
3.5. Strategies for Drug Delivery Across BBB
3.5.1. Increasing the Permeability of the BBB
3.5.2. Pharmacological Strategies to Facilitate Transport Across the BBB
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. BBB Non-Invasive Technology Providers
4.2.1. Distribution By Type Of Technology
4.2.1.1. Receptor Mediated Transcytosis
4.2.1.2. Increasing Permeability
4.2.1.3. Passive Diffusion
4.3. BBB Pipeline Drugs
4.3.1. Distribution by Type of Indication
4.3.2. Distribution by Phase of Development
4.3.3. Distribution by Technology Providers
4.4. BBB Penetrant Biologic Drugs: Distribution by Nature of Molecule
4.5. Other BBB Penetrant Drugs
4.6. Competing Technologies
4.7. Comparison Between Non-Invasive BBB Technologies and Competing BBB Technologies
 
5. NEUROLOGICAL INDICATIONS: MARKET POTENTIAL
5.1. Chapter Overview
5.2. Neurological Disorders: Market Potential Analysis
5.3. Neurological Indications: Market Potential
 
5.3.1. Alzheimer’s Disease
5.3.1.1. Overview
5.3.1.2. Facts
5.3.1.3. Example Marketed Drugs
5.3.1.4. Pipeline Drugs
5.3.1.5. Roots Analysis’ Perspective
 
5.3.2. Epilepsy
5.3.2.1. Overview
5.3.2.2. Facts
5.3.2.3. Example Marketed Drugs
5.3.2.4. Pipeline Drugs
5.3.2.5. Roots Analysis’ Perspective
 
5.3.3. Parkinson’s Disease
5.3.3.1. Overview
5.3.3.2. Facts
5.3.3.3. Example Marketed Drugs
5.3.3.4. Pipeline Drugs
5.3.3.5. Roots Analysis’ Perspective
 
5.3.4. Multiple Sclerosis
5.3.4.1. Overview
5.3.4.2. Facts
5.3.4.3. Example Marketed Drugs
5.3.4.4. Pipeline Drugs
5.3.4.5. Roots Analysis Perspective
 
5.3.5. Hunter’s Syndrome
5.3.5.1. Overview
5.3.5.2. Facts
5.3.5.3. Example Marketed Drugs
5.3.5.4. Pipeline Drugs
5.3.5.5. Roots Analysis’ Perspective
 
5.3.6. Brain Cancer
5.3.6.1. Overview
5.3.6.2. Facts
5.3.6.3. Example Marketed Drugs
5.3.6.4. Pipeline Drugs
5.3.6.5. Roots Analysis’ Perspective
 
6. BBB TECHNOLOGIES: UNDERLYING CONCEPTS
6.1. Chapter Overview
6.2. Receptor Mediated Transcytosis
6.2.1. Receptor-Mediated Targets for Brain Entry
6.2.2. Approaches Under RMT
6.2.2.1. Bispecific Antibodies
6.2.2.2. Trojan Horses
6.3. Increasing Permeability
6.4. Passive Diffusion
 
7. BBB TECHNOLOGY PROFILES
7.1. Chapter Overview
7.2. Technologies Based on Bispecific Antibody RMT Approach
 
7.2.1. Ossianix Blood-Brain Barrier Technology (Ossianix)
7.2.1.1. Technology Description
7.2.1.2. Company Overview
7.2.1.3. Pipeline
7.2.1.4. Partnerships/ Funding
7.2.2. Brain Shuttle Technology (Roche)
7.2.2.1. Technology Description
7.2.2.2. History of Development
7.2.2.3. Company Overview
7.2.2.4. Pipeline
7.2.2.5. Partnerships
 
7.2.3. Other Bispecific Antibodies Based Technologies
 
7.3. Technologies Based on Trojan Horse Approach
7.3.1. Transcend Technology (biOasis)
7.3.1.1. Technology Description
7.3.1.2. History of Development
7.3.1.3. Company Overview
7.3.1.4. Pipeline
7.3.1.5. Partnerships
7.3.1.6. Recent Developments
 
7.3.2. LRP Technology (Angiochem)
7.3.2.1. Technology Description
7.3.2.2. Company Overview
7.3.2.3. Pipeline
7.3.2.4. Partnerships
7.3.2.5. Funding
7.3.2.6. Recent Developments
 
7.3.3. IPRO Technology (Iproteos)
7.3.3.1. Protein-Protein Interactions (PPIs)
7.3.3.2. Protease Targeted Therapeutics
7.3.3.3. Technology Description
7.3.3.4. Identification of New Peptidomimetics
7.3.3.5. Company Overview
7.3.3.6. Pipeline
 
7.3.4. ArmaGen Technology Platform (ArmaGen)
7.3.4.1. Technology Description
7.3.4.2. Mode of Action
7.3.4.3. Company Overview
7.3.4.4. Pipeline
7.3.4.5. Partnerships
7.3.4.6. Funding
7.3.4.7. Recent Developments
 
7.3.5. Vect-Horus Technology Platform (Vect-Horus)
7.3.5.1. Technology Description
7.3.5.2. Company Overview
7.3.5.3. Pipeline
7.3.5.4. Partnerships
7.3.5.5. Funding
7.3.5.6. Recent Developments
 
7.3.6. G-Technology (BBB Therapeutics)
7.3.6.1. Technology Description
7.3.6.2. History of Development
7.3.6.3. Company Overview
7.3.6.4. Pipeline
7.3.6.5. Partnerships
7.3.6.6. Funding
7.3.6.7. Recent Developments
 
7.3.7. Nano BBB Technology Platform (Sagetis Biotech)
7.3.7.1. Technology Description
7.3.7.2. Company Overview
7.3.7.3. Pipeline
7.3.7.4. Funding
7.3.7.5. Partnerships
 
7.3.8. Other Technologies Based on Trojan Horse Approach
 
7.4. Technologies Based on Increasing the Permeability of BBB
7.4.1. SonoCloud Technology (CarThera)
7.4.1.1. Technology Description
7.4.1.2. Medical Applications
7.4.1.3. Company Overview
 
7.4.2. SPG Technology (BrainsGate)
7.4.2.1. Spheno-Palatine Ganglion
7.4.2.2. Technology Description
7.4.2.3. Current Developments Using this Technology
7.4.2.4. Company Overview
7.4.2.5. Funding
 
7.4.3. Other Technologies Based on Increasing Permeability of BBB
 
7.5. Technologies Based on Passive Diffusion
7.5.1. SciFluor Life Sciences
 
7.6. Other Non-Invasive BBB Technologies
7.6.1. SMART Molecule Technology (ICBI)
7.6.1.1. Technology Description
7.6.1.2. Company Overview
7.6.1.3. Pipeline
7.6.1.4. Partnerships
7.6.1.5. Recent Developments
 
7.6.2. Molecular Envelope Technology (Nanomerics)
7.6.2.1. Technology Description
7.6.2.2. Company Overview
7.6.2.3. Pipeline
7.6.2.4. Partnerships
7.6.2.5. Funding
7.6.2.6. Recent Developments
7.6.3. Other Approaches (JCR Pharma, Cyclenium, Cerecor, Lauren Sciences, Protheragen)
 
8. CASE STUDIES
8.1. Chapter Overview
 
8.2. Intrathecal Drug Delivery (Shire)
8.2.1. Technology Description
8.2.2. Company Overview
8.2.3. Pipeline
8.2.4. Recent Developments
 
8.3. TTP Technology (Eisai)
8.3.1. Technology Description
8.3.2. Company Overview
8.3.3. Pipeline
 
8.4. Technology Platform (BioMarin)
8.4.1. Technology Description
8.4.2. Company Overview
8.4.3. Pipeline
 
8.5. NeuroTrans Technology (Raptor Pharmaceuticals)
 
9. BBB TECHNOLOGIES: MARKET FORECASTING
9.1. Chapter Overview
9.1.1. Scope and Forecast Methodology
9.1.2. Overall Market Size and Forecast
9.2. ANG1005
9.3. 2B3-101
9.4. AGT-181
9.5. AGT 182
9.6. NP03
 
10. INTERVIEW TRANSCRIPTS
10.1. Xavier Rivero, Chief Operating Officer, Sagetis Biotech
10.2. Dr. Frank S Walsh, Ossianix, Founder & CEO
10.3. Rob Hutchison, biOasis, CEO & Chairman
 
11. CONCLUSION
11.1. BBB Technologies: Early Stages of Development but Highly Promising
11.2. Start-Ups Lead the Baton; Landscape Likely to Evolve in Mid-Long Term
11.3. Growing Patient Population and A Huge Unmet Need are Amongst the Several Growth Drivers
11.4. Concluding Remarks
 
12. APPENDIX 1: TABULATED DATA
 
13. APPENDIX 2: LIST OF COMPANIES

List of Figures

Figure 3.1 BBB: Historical Evolution
Figure 3.2 BBB: Developmental Milestones
Figure 3.3 BBB: Transport Systems
Figure 4.1 BBB Technologies: Distribution by Type of Technology
Figure 4.2 BBB RMT Technologies: Distribution by Process Followed
Figure 4.3 BBB Penetrant Drugs: Distribution by Target Indication
Figure 4.4 BBB Penetrant Drugs: Distribution by Phase of Development
Figure 4.5 BBB Penetrant Drugs: Distribution by Technology Developers
Figure 4.6 BBB Penetrant Biologic Drugs: Distribution by Nature of Molecule
Figure 5.1 Neurological Indications: Bubble Chart Analysis
Figure 5.2 Alzheimer’s Disease: Market Potential
Figure 5.3 Epilepsy: Market Potential
Figure 5.4 Parkinson’s disease: Market Potential
Figure 5.5 Multiple Sclerosis: Market Potential
Figure 5.6 Hunter’s Syndrome: Market Potential
Figure 5.7 Brain Cancer: Market Potential
Figure 7.1 Nanomerics: Fabrication of a MET nanoparticle
Figure 9.1 BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
Figure 9.2 BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Figure 9.3 ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
Figure 9.4 ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Figure 9.5 2B3101 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
Figure 9.6 2B3101 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Figure 9.7 AGT181 Sales Forecast: Mid-Long Terms, 2023 - 2030: Base Scenario (USD Million)
Figure 9.8 AGT182 Sales Forecast: Mid-Long Terms, 2023 - 2030: Base Scenario (USD Million)
Figure 9.9 NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
Figure 9.10 NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Figure 11.1 BBB Technologies Market: Key Growth Drivers
Figure 11.2 BBB Technologies Market, 2019, 2025, 2030 (USD Million)

List of Tables

Table 3.1  Component of Human Brain: Important Characteristics
Table 3.2 CNSDrug Delivery Devices
Table 3.3  BBB: Functions Involved
Table 3.4 Saturable Blood to Brain Transporters
Table 4.1  BBB Technology Platforms
Table 4.2  BBB Technologies: Pipeline Drugs 
Table 4.3  Other Potential Candidates
Table 4.4  Competing Technologies
Table 4.5  Comparison Chart: Non-Invasive BBB Technologies v/s Competing BBB Technologies
Table 5.1  Alzheimer’s disease: Key Facts
Table 5.2  Alzheimer’s disease: Example Marketed Drugs 
Table 5.3 Epilepsy: Key Facts
Table 5.4  Epilepsy: Example Marketed Drugs 
Table 5.5 Parkinson’s Disease: Key Facts
Table 5.6  Parkinson’s Disease: Example Marketed Drugs 
Table 5.7  Parkinson’s disease: Pipeline Drugs Based on BBB Technologies
Table 5.8  Multiple Sclerosis: Key Facts
Table 5.9  Multiple Sclerosis: Example Marketed Drugs 
Table 5.10  Hunter’s Syndrome: Key Facts
Table 5.11  Hunter’s Syndrome: Pipeline Drugs Based on BBB Technologies
Table 5.12  Brain Cancer: Key Facts
Table 5.13  Brain Cancer: Example Marketed Drugs
Table 5.14  Brain Cancer: Pipeline Drugs Based on BBB Technologies
Table 7.1  BBB Technologies: Concepts Involved
Table 7.2 Ossianix: Company Overview
Table 7.3 Roche: Company Overview
Table 7.4  Roche: Neurology Pipeline
Table 7.5  Other Bispecific Antibodies Based BBB Technologies 
Table 7.6  biOasis: Company Overview
Table 7.7 biOasis: Pipeline
Table 7.8 biOasis: Partnerships Deals
Table 7.9  Angiochem: Company Overview 
Table 7.10  Angiochem: Pipeline
Table 7.11  Iproteos: Company Overview
Table 7.12  Iproteos: Pipeline
Table 7.13  ArmaGen: Company Overview
Table 7.14  ArmaGen: Pipeline
Table 7.15  Vect-Horus: Company Overview
Table 7.16  Vect-Horus: Pipeline
Table 7.17  Vect-Horus: Patents
Table 7.18  BBB Therapeutics: Company Overview
Table 7.19  BBB Therapeutics: Pipeline
Table 7.20  BBB Therapeutics: Partnerships
Table 7.21  Sagetis Biotech: Company Overview
Table 7.22  Sagetis Biotech: Pipeline
Table 7.23  Other BBB Technologies Based on Trojan Horse Approach
Table 7.24  CarThera: Company Overview
Table 7.25  BrainsGate: Company Overview
Table 7.26  Other BBB Technologies Based on Increasing the Permeability
Table 7.27  ICBI: Company Overview
Table 7.28  ICBI: Pipeline
Table 7.29  Nanomerics: Company Overview
Table 7.30  Nanomerics: Pipeline
Table 7.31  Other Non-Invasive BBB Approaches
Table 8.1 Shire: Company Overview
Table 8.2  Shire: Neurology Pipeline
Table 8.3 Eisai: Company Overview
Table 8.4 Eisai: Neurology Pipeline
Table 8.5 BioMarin: Company Overview
Table 8.6 BioMarin: Neurology Pipeline
Table 9.1  Current Development Phase and Expected Launch Year of Drugs in Clinical Development
Table 12.1  BBB Technologies: Distribution by Type of Technology
Table 12.2  BBB RMT Technologies: Distribution by Process Followed
Table 12.3  BBB Penetrant Drugs: Distribution by Target Indication
Table 12.4  BBB Penetrant Drugs: Distribution by Phase of Development 
Table 12.5  BBB Penetrant Drugs: Distribution by Technology Developers
Table 12.6  BBB Penetrant Biologic Drugs: Distribution by Nature of Molecule
Table 12.7  BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
Table 12.8  BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Table 12.9  BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Conservative Scenario (USD Million)
Table 12.10  BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
Table 12.11  BBB Technologies Sales Forecast: Short-Mid Term, 2019 - 2025: Optimistic Scenario (USD Million)
Table 12.12  BBB Technologies Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)
Table 12.13  ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Base Scenario (USD Million)
Table 12.14  ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Table 12.15  ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Conservative Scenario (USD Million)
Table 12.16  ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
Table 12.17  ANG1005 Sales Forecast: Short-Mid Term, 2019 - 2025: Optimistic Scenario (USD Million)
Table 12.18  ANG1005 Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)
Table 12.19  2B3-101 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
Table 12.20  2B3-101 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Table 12.21  2B3-101 Sales Forecast: Short-Mid Term, 2020 - 2025: Conservative Scenario (USD Million)
Table 12.22  2B3-101 Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
Table 12.23  2B3-101 Sales Forecast: Short-Mid Term, 2020 - 2025: Optimistic Scenario (USD Million)
Table 12.24  2B3-101 Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)
Table 12.25  AGT-181 Sales Forecast: Mid-Long Term, 2023 - 2030: Base Scenario (USD Million)
Table 12.26  AGT-181 Sales Forecast: Mid-Long Term, 2023 - 2030: Conservative Scenario (USD Million)
Table 12.27  AGT-181 Sales Forecast: Mid-Long Term, 2023 - 2030: Optimistic Scenario (USD Million)
Table 12.28  AGT-182 Sales Forecast: Mid-Long Term, 2023 - 2030: Base Scenario (USD Million)
Table 12.29  AGT-182 Sales Forecast: Mid-Long Term, 2023 - 2030: Conservative Scenario (USD Million)
Table 12.30  AGT-182 Sales Forecast: Mid-Long Term, 2023 - 2030: Optimistic Scenario (USD Million)
Table 12.31  NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Base Scenario (USD Million)
Table 12.32  NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Base Scenario (USD Million)
Table 12.33  NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Conservative Scenario (USD Million)
Table 12.34  NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Conservative Scenario (USD Million)
Table 12.35  NP03 Sales Forecast: Short-Mid Term, 2020 - 2025: Optimistic Scenario (USD Million)
Table 12.36  NP03 Sales Forecast: Mid-Long Term, 2025 - 2030: Optimistic Scenario (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. Abbott
  2. AbbVie
  3. Accera
  4. Acelot
  5. Acorda
  6. Acyclone Life Sciences
  7. Advanced BioHealing
  8. Aescap Ventures
  9. Affectis Pharmaceuticals
  10. Agate Medical Investments
  11. ALS association
  12. Angiochem
  13. Antea
  14. Aphios
  15. ArmaGen
  16. ArQule
  17. Array BioPharma
  18. Arrowhead Research Corp
  19. Artenga
  20. ASCIL Biopharma
  21. Asebio
  22. Atlas Venture
  23. Aurin Biotech
  24. AZ Therapies
  25. Bach Pharma
  26. Bayer
  27. BBB Therapeutics
  28. BDC Venture Capital
  29. BGN Technologies
  30. Bind Therapeutics
  31. BioAdvance
  32. Bioasis
  33. Biocat
  34. Biocrea
  35. Biogen Idec
  36. Bioline Rx
  37. BioMarin
  38. Biovista
  39. BMS
  40. Boehringer Ingelheim
  41. Boehringer Ingelheim Venture Fund
  42. Boston Scientific
  43. BPI France
  44. BrainsGate
  45. CarThera
  46. CDTI
  47. CEA
  48. Cerecor
  49. Chronos Therapeutics
  50. Cib-Geigy
  51. Cipio Partners
  52. CNRS
  53. Cortice Biosciences
  54. Corvitex
  55. Crinetics
  56. Cyclenium
  57. Dainippon Sumitomo Pharma
  58. Debiopharm
  59. Deciphera
  60. DEKK-TEC
  61. Del Mar Pharma
  62. Drugs Ford
  63. EIP Pharma
  64. Eisai
  65. Elan Pharmaceuticals
  66. Elron Electronic Industries Ltd
  67. Ethris GmbH
  68. Evgen
  69. FerroKinBioSciences
  70. Flocel
  71. Fluorinov Pharma
  72. Fondazione Telethon
  73. Forest Laboratories
  74. Genervon Biopharmaceuticals
  75. Genzyme
  76. GlaxoSmithKline
  77. Global Investment
  78. Heptares
  79. ICB International
  80. Immune Pharmaceuticals
  81. Impax Labs
  82. Impel Neuro Pharma
  83. ImStar
  84. Infinity
  85. INSERM
  86. Iproteos
  87. IRB Barcelona
  88. Janssen
  89. JCR Pharma
  90. Johnson & Johnson
  91. Jonghoud International BV
  92. Kadmon Corporation
  93. KalGene
  94. Krisani Bio
  95. Lixte
  96. Lotus Tissue
  97. Lumena Pharmaceuticals
  98. Lundbeck Pharmaceuticals
  99. Medesis Pharma
  100. MedImmune
  101. Medtronic
  102. Merck
  103. Michael J. Fox Foundation
  104. Minoryx
  105. Mitsui & Co.
  106. MMV financial
  107. Morphotek
  108. Movetis
  109. Mylan
  110. Mystic Pharmaceuticals
  111. nanoLIMIT Therapeutics
  112. Nanomerics
  113. Nativis
  114. Nektar Therapeutics
  115. Neuraltus Pharma
  116. Neuren Pharmaceuticals
  117. NeuroAdjuvants
  118. Neuronix
  119. NeuroSolis
  120. NeuroTransit
  121. NeuroVive
  122. New River
  123. NewGen Therapeutics
  124. NexGenix
  125. Novartis
  126. Novogen
  127. NPS Pharma
  128. Nsgene
  129. OncoNanoBBB
  130. OptiNose
  131. Ortho-McNeil Pharmaceuticals
  132. Oryzon
  133. OSEO
  134. Ossianix
  135. Palobiofarma
  136. ParcCientific
  137. Parke-Davis
  138. Perfusion Technology
  139. Pervasis Therapeutics
  140. Pharmaphenix
  141. Pharmadex
  142. Pharmidex Pharmaceutical Services
  143. Pitango Venture Capital
  144. Plexxikon
  145. Premacure AB
  146. Prexton Therapeutics
  147. Protagenic
  148. ProteoTech
  149. Prothena
  150. Protheragen
  151. PTC Therapeutics
  152. Radius Pharma
  153. Raptor
  154. Repligen
  155. Roche
  156. Sagetis Biotech
  157. SangamoBioSciences
  158. Sanofi
  159. Santaris Pharma
  160. Schering-Plough
  161. Schwarz Pharma
  162. SciFlourLife Sciences
  163. Shire
  164. Siena Biotech
  165. Sihuan
  166. SimPore
  167. SmithKline Beecham
  168. Solvo Biotechnology
  169. Sovicell
  170. Synageva BioPharma Corp
  171. Synageva BioPharma Corp.
  172. Synapse technologies
  173. Tactical Therapeutics
  174. Takeda
  175. Teva
  176. Teva Pharmaceuticals
  177. Transition Therapeutics
  178. Transmolecular Inc.
  179. UCB
  180. UCB Pharma
  181. Vect-Horus
  182. ViroPharma
  183. VistaGen Therapeutics
  184. VoltMed
  185. Xenoport
  186. Zywie

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.